NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity

NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield, PainShield and WoundShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a non-binding letter of intent (the “LOI”) with APOGEPHA Arzneimittel GmbH (“APOGEPHA”) in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix’s premiere UroShield product in Germany and other European markets.

With a history that dates back over 100 years, APOGEPHA has established itself as a high quality, dedicated specialist in the field of urology. Under the terms of the LOI, APOGEPHA will commence a comprehensive market evaluation on how UroShield fits into the pathway of care for patients with long term catheters. The goal of the LOI, and subsequent findings, will be for both NanoVibronix and APOGEPHA to better understand the feasibility of a distribution deal between both companies.

Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, “APOGEPHA’s impeccable reputation in the field of urology coupled with their intimate knowledge of market access, reimbursement strategies and speed to market decisions, gives us great optimism about UroShield’s potential for success in Europe and APOGEPHA’s pivotal role in its distribution. As a solution for patients who are poorly served though the traditional pharmaceutical route of simple antibiotics, UroShield has the potential to become a true standard of care in Europe, and we look forward to working with APOGEPHA to fully understand and model this opportunity.”

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com